Medicenna Therapeutics Corp.
MDNAF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001807983
No open-market purchases or sales by Medicenna Therapeutics Corp. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q4 2021 vs. Q3 2021
How the institutions holding Medicenna Therapeutics Corp. changed between Q3 2021 and Q4 2021.
All holders in Q4 2021All holders in Q3 2021
| Measure | Q3 2021 | Q4 2021 | Change |
|---|---|---|---|
| Holders | 25 | 23 | −2 |
| Shares | 3.05M | 4.44M | +1.40M (+45.9%) |
| Value | $8.66M | $7.42M | −$1.25M (−14.4%) |
New holders (2)
Institutions that held Medicenna Therapeutics Corp. at the end of Q4 2021 but not at the end of Q3 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| UBS Group AG | 2,882 | $5.00K | 0.00% |
| TAP Consulting, LLC | 500 | $1.00K | 0.00% |
Sold out (4)
Institutions that held Medicenna Therapeutics Corp. at the end of Q3 2021 and filed for Q4 2021 without it.
| Institution | Shares, Q3 2021 | Value, Q3 2021 |
|---|---|---|
| Bank of Montreal | 38,053 | $101.0K |
| Davenport & Co LLC | 27,750 | $77.0K |
| Deutsche Bank AG | 22,900 | $64.0K |
| Gerber Kawasaki Wealth & Investment Management | 1 | – |